A research team used the urine proteome model composed of LPGDS, transferrin, AGP-1, ceruloplasmin, MCP-1 and sVCAM-1 as a potential biomarker group to identify active LN and predict the efficacy of RTX [51,52]. Here, CCL2 is linked to lobular neoplasia.